Sun aims to strongarm Taro shareholders

India's Sun Pharmaceuticals just won't take no for an answer. After its merger deal with Israel's Taro Pharmaceuticals fell apart last month, Sun now says it's going to try to force the company's controlling shareholders to sell out. "We will do everything required to preserve our rights," Sun's chairman said in a statement. Both companies are suing over the collapsed deal. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.